ArgenX shares are attracting renewed investor attention following the company's inclusion in the Euro Stoxx 50, a development that has broadened its appeal to index-tracking funds and European equity investors.
The Belgian-Dutch biotech firm, which was relatively obscure in the broader market just months ago, is now benefiting from the structural buying pressure that accompanies entry into one of Europe's premier benchmark indices.
ArgenX shares climbed more than 4% on Thursday, erasing previous session losses and emerging as a primary catalyst for a rally on the Brussels stock exchange.
The stock's momentum has been evident in recent trading sessions.
ArgenX shares climbed more than 4% on Thursday, erasing previous session losses and emerging as a primary catalyst for a rally on the Brussels stock exchange.
This recovery helped push the Belgian benchmark higher, underscoring the outsized influence the biotech name is beginning to exert on regional market sentiment.
The shift in ArgenX's market profile reflects a broader trend of European biotech firms gaining traction as investors seek exposure to high-growth healthcare assets outside the US.